Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 4/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.31 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL984874 | 0.88 | HCAR1 (0.39) | HCAR1RXRAGRIN1GRIN2BALDH1A1 | |
| SCHEMBL985248 | 0.87 | P2RX7 (0.46) | HCAR1P2RX7ALDH1A1 | |
| SCHEMBL986522 | 0.84 | P2RX7 (0.39) | HCAR1P2RX7IDO1KAT2BRXRA | |
| SCHEMBL982367 | 0.83 | HCAR1 (0.37) | HCAR1P2RX7IDO1KAT2BRXRA | |
| SCHEMBL984870 | 0.78 | NOTUM (0.36) | HCAR1P2RX7IDO1KAT2BRXRA | |
| SCHEMBL985336 | 0.75 | HCAR1 (0.37) | HCAR1P2RX7IDO1KAT2BRXRA | |
| SCHEMBL986259 | 0.73 | ALDH1A1 (0.41) | HCAR1P2RX7RXRAGRIN1GRIN2B | |
| SCHEMBL982271 | 0.72 | P2RX7 (0.49) | HCAR1P2RX7ALDH1A1NOTUM | |
| SCHEMBL985906 | 0.72 | HCAR1 (0.36) | HCAR1RXRAGRIN1GRIN2BALDH1A1 | |
| SCHEMBL986356 | 0.71 | P2RX7 (0.41) | HCAR1P2RX7PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101479255-B | C-MET protein kinase inhibitors for the treatment of proliferative disorders | VERTEX PHARMA | 2013-05-01 | — | — | CN | disclosed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| EP-2004625-B1 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMA (US) | 2009-12-30 | — | — | EP | disclosed |
| CN-101479255-A | c-MET protein kinase inhibitors for the treatment of proliferative disorders | VERTEX PHARMA (US) | 2009-07-08 | — | — | CN | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | HCAR1 4131/4885P2RX7 3624/4885IDO1 4573/4885 |
| US-20070254868-A1 | C-MET protein kinase inhibitors | MET, PRKCH, ABL1 | HCAR1 4131/4885P2RX7 3624/4885IDO1 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.